Citi analyst Joanne Wuensch opened a “90 data positive catalyst watch” on Haemonetics while keeping a Neutral rating on the name with a $94 price target into the fiscal Q2 report. The analyst says continued Plasma momentum will allow Haemonetics to be one of the few “clean” stories this reporting cycle. The firm expects management to again beat expectations and raise fiscal year guidance.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on HAE:
- Haemonetics announces European expansion for Vascade MVP
- Haemonetics price target raised to $114 from $111 at Barrington
- Haemonetics raises FY24 adjusted EPS view to $3.60-$3.90 from $3.45-$3.75
- Haemonetics 1st Quarter Fiscal Year 2024 Earnings Release Available on Investor Relations Website
- Haemonetics reports Q1 adjusted EPS $1.05, consensus 73c